QUEST DIAGNOSTICS INC

Quest Diagnostics Incorporated announced that Catherine T. Doherty will retire in July 2027. Until her retirement, Ms. Doherty will transition to a new role as Executive Vice President, effective November 1, 2026. In this new capacity, she will oversee health systems, the company's joint venture with Corewell Health, and Project Nova, a multi-year initiative to modernize business processes. Her compensation, including base salary and incentive targets, will remain unchanged. Additionally, she will receive an equity award valued at $1,200,000, primarily in restricted stock units.

Quest Diagnostics reported strong financial results for the second quarter and first half of 2026, with significant increases in net revenues, net income, and diluted EPS compared to the prior year. The company also completed a strategic joint venture with Corewell Health to expand laboratory testing in Michigan and managed its debt profile by issuing new senior notes and repaying maturing ones. These actions align with the ongoing Invigorate program aimed at driving savings and productivity.

Quest Diagnostics reported strong financial results for the second quarter ended June 30, 2026, with revenues increasing 10.2% to $3.04 billion and adjusted diluted EPS growing 19.1% to $3.12. Following this performance, the company raised its full-year 2026 guidance, now expecting revenues between $11.95 billion and $12.05 billion, and adjusted diluted EPS between $11.05 and $11.25. Key highlights include robust organic revenue growth, advancements in Co-Lab Solutions, and double-digit growth in Advanced Diagnostics.

Quest Diagnostics announced the pricing of a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036. The company expects to receive the net proceeds on May 6, 2026, and intends to use them for general corporate purposes. This may include the repayment of its $500 million 3.45% Senior Notes maturing on June 1, 2026.

Quest Diagnostics Incorporated reported its financial results for the first quarter ended March 31, 2026. The company achieved net revenues of $2,895 million, marking a 9.2% increase compared to $2,652 million in the same period of the previous year. Operating costs and expenses totaled $2,496 million for the quarter, including $1,953 million for cost of services and $504 million for selling, general and administrative expenses.

Quest Diagnostics reported strong first-quarter 2026 financial results, with revenues increasing 9.2% to $2.90 billion, driven by 9.0% organic growth. Reported diluted EPS rose 15.5% to $2.24, and adjusted diluted EPS increased 13.1% to $2.50. Following these results, the company raised its full-year 2026 reported and adjusted diluted EPS guidance, reflecting disciplined execution and a positive outlook.